Orotic Acid

Orotic Acid

SCHEMBL174876

CC1CNCCc2ccccc21.O=C(O)c1cc(=O)[nH]c(=O)[nH]1

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 16/20 0.59
HTR2A P28223 15/20 0.59
HTR2B P41595 14/20 0.59
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
ADRB1 P08588 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
CNR1 P21554 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
HRH1 P35367 1/20 0.43
KCNH2 Q12809 1/20 0.43
TAAR1 Q96RJ0 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lorcaserin SCHEMBL175008 0.87 HTR2A (0.63) HTR2CHTR2AHTR2BALDH1A1LMNA
Lorcaserin SCHEMBL170984 0.87 HTR2A (0.63) HTR2CHTR2AHTR2BALDH1A1LMNA
Orotic Acid SCHEMBL162920 0.84 ALDH1A1 (0.45) HTR2CHTR2AHTR2BALDH1A1LMNA
Orotic Acid SCHEMBL175081 0.83 ALDH1A1 (0.62) HTR2CHTR2BALDH1A1LMNATSHR
SCHEMBL175082 0.77 CYP1A2 (0.41) HTR2CHTR2AHTR2BALDH1A1LMNA
SCHEMBL164205 0.77 HTR2C (1.00) HTR2CHTR2AHTR2BADRB1HTR1A
Fumaric Acid SCHEMBL175130 0.76 HTR2C (0.74) HTR2CHTR2AHTR2BLMNAADRB1
Succinic Acid SCHEMBL170444 0.76 HTR2C (0.74) HTR2CHTR2AHTR2BADRB1HTR1A
Glycolic Acid SCHEMBL173573 0.76 HTR2C (0.74) HTR2CHTR2AHTR2BADRB1HTR1A
Maleic Acid SCHEMBL174415 0.76 HTR2C (0.74) HTR2CHTR2AHTR2BLMNAADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611449-A1 ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT Arena Pharmaceuticals, Inc. (US) 2013-07-10 EP disclosed
EP-2611427-A2 MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT& xA; Arena Pharmaceuticals, Inc. (US) 2013-07-10 EP disclosed
WO-2012030927-A2 MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT ARENA PHARMACEUTICALS, INC. (US) 2012-03-08 WO disclosed
WO-2012030939-A1 ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT ARENA PHARMACEUTICALS, INC. (US) 2012-03-08 WO disclosed